TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01740141

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plexus brachialis block

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plexus brachialis block
Study: NCT05208671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NOURISH Food Box
Description: Selection of healthy groceries designed to reduce chronic inflammation and improve insulin resistance with healthy cooking/self-care curriculum
Study: NCT01401907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early palliative care
Description: patient assigned to the intervention will receive early palliative care along with standard oncology care.
Study: NCT01323634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg
Description: inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 250mcg/ salmeterol 50mcg
Description: inhalation powder
Study: NCT02607696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Hemitartarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Hemitartarate
Study: NCT02409368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT04176302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parkinson Holter
Description: The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motor fluctuations diary
Description: The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional clinical practice
Description: The neurologists will receive the patient \& caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
Study: NCT01723384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03223896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone hydrochloride 20mg/ml
Description: Nasal spray
Study: NCT02737709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin regimen
Description: Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
Study: NCT00101881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillation (biphasic versus monophasic shock)
Description: Administration of monophasic or biphasic waveform defibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Defibrillation (biphasic versus monophasic shock)
Description: Administration of monophasic or biphasic waveform defibrillation
Study: NCT01116882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Study: NCT02673840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: 2 mg of Ketotifen, twice a day for a total of ten (10) doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
Study: NCT02879422

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis
Study: NCT01879215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nailing of the tibia
Description: Standard care surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nailing of the tibia
Description: Standard care surgery
Study: NCT03069612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
Study: NCT01530165

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life style intervention
Description: The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat \<30 proportion of total energy, saturated fat \<10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
Study: NCT01001026

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix
Description: Adults: One dose Arepanrix vaccine given IM (0.5 mL)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix
Description: Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
Study: NCT03056222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation catheter
Description: Ablation of paroxysmal atrial fibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation catheter
Description: Ablation of paroxysmal atrial fibrillation
Study: NCT02323217

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]BU99008
Description: Baseline Scan, Test-ReTest or Dosimetry

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idazoxan
Description: Idazoxan block of \[11C\]BU99008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isocarboxazid
Description: Isocarboxazid block of \[11C\]BU99008
Study: NCT03549182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (100g)(Acute Tryptophan Depletion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (100g)(Acute Tryptophan Depletion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (100g)(Acute Tryptophan Depletion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (100g)(Acute Tryptophan Depletion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo treatment
Description: oral administration of placebo (102.3g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo treatment
Description: oral administration of placebo (102.3g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo treatment
Description: oral administration of placebo (102.3g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo treatment
Description: oral administration of placebo (102.3g)
Study: NCT02480387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir FDC
Study: NCT04027517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951
Description: Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Intravenous administration~* Dose adjustments as maintenance dose is allowed according to the result of Hb level.
Study: NCT02839200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 5 mg
Description: Capsule for oral administration containing ACT-541468 at a strength of 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 10 mg
Description: Capsule for oral administration containing ACT-541468 at a strength of 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg
Description: Capsule for oral administration containing ACT-541468 at a strength of 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg
Description: Capsule for oral administration containing ACT-541468 at a strength of 25 mg
Study: NCT02622958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B
Description: PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg
Study: NCT01941797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interruption of oral hygiene

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interruption of oral hygiene
Study: NCT04842656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation
Description: Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release technique alongwith conventional treatment
Description: Patients in Group A will receive active release technique.ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformisand direct pressure isapplied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.
Study: NCT04278001

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual 24-hour ABPM
Description: Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
Study: NCT03695666

Intervention type: OTHER
Intervention: Clerical policy
Description: Clerical policy introduction
Study: NCT02737839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepping On Education Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Questionnaire
Description: -Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-Balance Evaluation Systems Test
Description: * The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~* Balance testing will take approximately 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GAITRite
Description: * Gait will be assessed using the 4.87-m GAITRite~* The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precise measure of movement testing
Description: We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up \& Go, 3) Dual Timed Up \& Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
Study: NCT01080495

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TEE (transesophageal echocardiography)
Description: a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
Study: NCT04409353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
Study: NCT04417946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP messages
Description: The peer leaders and the study staff will post PrEP related health messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heath messages
Description: The peer leaders and study staff will post general health messages that are not related to sexual health
Study: NCT00923533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
Study: NCT01193920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 20/20/20 μg
Description: Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Subjects received two injection of saline solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg
Description: Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg
Description: Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 5/5/5 μg
Description: Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Subjects received one injection of saline solution.
Study: NCT02230553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Study: NCT03217305

Intervention type: DEVICE
Group type: OTHER
Intervention: NAVA
Description: Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
Study: NCT04341766

Intervention type: OTHER
Intervention: No special intervention
Description: No special intervention : Ultrasound data will be collected
Study: NCT02924142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OT Cap attachment
Description: The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
Study: NCT00607022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant
Description: Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant
Description: Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant
Description: Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
Study: NCT02727465

Intervention type: OTHER
Intervention: Meningitis cases
Description: None - blood draw only
Study: NCT03244735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atkins diet
Description: A nutritional regimen characterized by high fat low carbohydrate intake.
Study: NCT00969410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-299
Description: AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
Study: NCT02846753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans catheter heart valve replacement
Description: trans catheter heart valve replacement
Study: NCT00227890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI/CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT/TU
Study: NCT02767128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fer-In-Sol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fer-In-Sol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution
Study: NCT01795027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Description: 6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 single
Description: 16 courses S-1 single after d D2 resection
Study: NCT01079130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol
Description: Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol
Description: Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol
Description: Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol
Description: Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Salmeterol
Description: Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).